Technology Prognosis

tracking technologies before you have to make a decision

Prognosis is a horizon scanning service that monitors emerging health technologies as they go through clinical trial development and the regulatory approval process.

View a sampling of our Prognosis reports.

Hemlibra (Emicizumab-kxwh)

November 17, 2017 Technology Prognosis

Emicizumab is a bispecific monoclonal antibody that mimics the coagulation function of clotting factor VIII (FVIII); it is proposed to address an unmet treatment need for patients with hemophilia A who have developed inhibitors to FVIII. This “nonfactor” investigational therapy bridges activated clotting factors IX and X, thereby fulfilling the role normally played by activated FVIII in the coagulation cascade.   

Hydrus Microstent

November 15, 2017 Technology Prognosis

The Hydrus microstent for permanent implantation is proposed to reduce intraocular pressure in patients with mild-to-moderate glaucoma undergoing cataract surgery. The device is permanently implanted in Schlemm’s canal, where it helps to open the trabecular meshwork and dilate the canal, thereby augmenting aqueous humor outflow from the anterior chamber to the fluid collector channel. Hydrus is implanted ab interno (from inside the eye) using a proprietary injector delivery system.

RBP-6000 for Opioid Use Disorder

November 13, 2017 Technology Prognosis

RBP-6000 is an extended-release formulation of buprenorphine intended for the treatment of moderate-to-severe opioid use disorder in patients who have undergone induction with a transmucosal buprenorphine-containing product to suppress opioid withdrawal signs and symptoms.. RBP-6000 utilizes the Atrigel Delivery System, which consists of a biodegradable polymer dissolved in a biocompatible solvent. RBP-6000 is administered once monthly by subcutaneous (SC) injection in the abdominal region, and provides sustained plasma levels of buprenorphine over the dosing interval. RBP-6000 is injected as a solution, and subsequent precipitation of the polymer creates a solid depot containing buprenorphine. Buprenorphine is released via diffusion and biodegradation...

Spinraza (Nusinersen)

November 6, 2017 Technology Prognosis

Spinraza is ann intrathecally administered antisense oligonucleotide (ASO) for treatment of spinal muscular atrophy (SMA). SMA is caused by deletions or mutations in the survival motor neuron 1 (SMN1) gene; these gene alterations lead to a deficiency of survival motor neuron (SMN) protein, which is critical for the maintenance of motor neurons. Spinraza is designed to alter the splicing of SMN2, a gene that is nearly identical to SMN1, in order to increase production of fully functional SMN protein. Spinraza is delivered by intrathecal injection, since ASO drugs do not cross an intact blood–brain barrier when delivered systemically. The drug...

Viaskin Epicutaneous Immunotherapy (EPIT) for Treatment of Peanut Allergy (Viaskin Peanut)

November 1, 2017 Technology Prognosis

Viaskin Peanut is an epicutaneously delivered immunotherapy in development for the treatment of peanut allergy. It is designed to gradually “train” a patient’s immune system to tolerate peanuts.